Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

Cited by (1,000)

Items 801–900 of 1,000

1. Evaluation of Pharmacokinetic and Pharmacodynamic Interactions when Lenalidomide is Co-administered with Warfarin in a Randomized Clinical Trial Setting
   Daniel Weiß, Robert Knight, Simon Yuji Zhou, Maria Palmisano, Nianhang Chen · 2015 · Clinical Drug Investigation
2. Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database
   Pascale Olivier, Anne-Charlotte Teisseyre, Jean‐Louis Montastruc · 2013 · Medical Oncology
3. Cost–effectiveness of lenalidomide in multiple myeloma
   Steve Schey, Irene J Higginson · 2010 · Expert Review of Pharmacoeconomics & Outcomes Research
4. Update on the pharmacotherapy for myelodysplastic syndromes
   Vu H. Duong, Rami S. Komrokji, Alan F. List · 2014 · Expert Opinion on Pharmacotherapy
5. Diagnosis and Treatment of Multiple Myeloma
   S. Vincent Rajkumar, Robert A. Kyle · 2012 · Springer eBooks
6. Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis
   Koji Kawamura, Takashi Ikeda, Shotaro Hagiwara, Takehiko Mori, Atsushi Shinagawa, Kaichi Nishiwaki, Kazuteru Ohashi, Shiro Kubonishi, Takahiro Fukuda, Toshiro Ito et al. · 2016 · Leukemia & lymphoma/Leukemia and lymphoma
7. Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study
   Shinsuke Iida, Hirokazu Nagai, Gen Kinoshita, Masafumi Miyoshi, Michael D. H. Robbins, Dimple Pandya, Eric W. Bleickardt, Takaaki Chou · 2016 · International Journal of Hematology
8. Successful desensitization to pomalidomide in a patient with POEMS syndrome with delayed-type hypersensitivity to immunomodulatory imid drugs
   Francesco Grandoni, Grégoire Stalder, Amélie Borgeat Kaeser, Camillo Ribi, Anne Cairoli, Sabine Blum · 2019 · Leukemia & lymphoma/Leukemia and lymphoma
9. The clinical- and cost-effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy: an evidence review of the submission from Celgene
   Martin Hoyle, G Rogers, Ruth Garside, Tiffany Moxham, Ken Stein · 2008
10. Old and new generation immunomodulatory drugs in multiple myeloma
    Daniele Derudas, Francesca Capraro, Giovanni Martinelli, Claudio Cerchione · 2021 · Panminerva Medica
11. Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
    Sascha Alexander Tuchman, Nelson Jen An Chao, Cristina Gasparetto · 2012 · Advances in Hematology
12. Cost-effectiveness of lenalidomide in combination with dexamethasone compared to bortezomib in combination with dexamethasone for the second-line treatment of multiple myeloma in Chile
    Susana Aceituno, Irmina Gozalbo, Marilena Appierto, Luís Lizán · 2018 · Medwave
13. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma
    Lucia Pantani, Annamaria Brioli, Paola Tacchetti, Beatrice Anna Zannetti, Katia Mancuso, Serena Rocchi, Marina Martello, Ilaria Rizzello, Carolina Terragna, Elena Zamagni et al. · 2015 · Expert Review of Hematology
14. Molecular Glue Degraders: From Serendipity to Hunting and Design
    Luis Nieto‐Barrado, Ana Domostegui, Cristina Mayor‐Ruiz · 2022 · Wiley eBooks
15. Approaches To Managing Relapsed Myeloma: Switching Drug Class or Retreatment With Same Drug Class?
    Rohit Vijjhalwar, Aarthi Kannan, María Cynthia Fuentes-Lacouture, Karthik Ramasamy · 2025 · Indian Journal of Hematology and Blood Transfusion
16. Using protein turnover assay to explore the drug mechanism of Carfilzomib
    Yonghui Tao, Xinyu Ding, Caiwei Jia, Chengcheng Wang, Chuanyin Li · 2024 · Acta Biochimica et Biophysica Sinica
17. Design and synthetic approaches to thalidomide based small molecule degraders
    Ajeet Kumar, Gulshan Kumar, Nidhi Kalia, Priya Ranjan Sahoo · 2025 · European Journal of Medicinal Chemistry
18. Managing multiple myeloma in the over 70s: A review
    Andrew John King, Sarah Gooding, Karthik Ramasamy · 2014 · Maturitas
19. Systematic Review and Network Meta-Analysis of Treatment Outcomes for Multiple Myeloma
    Xavier Armoiry, Alexander Tsertsvadze, Martin J Connock, G. J. Meléndez‐Torres, Aileen Clarke · 2017 · Journal of Clinical Oncology
20. A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma
    on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT), Shin‐ichi Fuchida, Kazutaka Sunami, Morio Matsumoto, Hirokazu Okumura, Tohru Murayama, Toshihiro Miyamoto, Eichi Otsuka, Naohito Fujishima, Tohru Izumi et al. · 2018 · International Journal of Hematology
21. Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma – analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies
    Vladimír Maisnar, Zuzana Štefániková, I. Spicka, Luděk Pour, Jiří Minařík, M. Flochova, Jakub Radocha, Evžen Gregora, Natalia Stecova, Tomáš Jelı́nek et al. · 2019 · Neoplasma
22. Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2013
    Anna Dmoszyńska, Adam Walter‐Croneck, Lidia Usnarska‐Zubkiewicz, Beata M. Stella-Holowiecka, Jan Andrzej Walewski, Grzegorz Charliński, W Wiktor-Jędrzejczak, Elżbieta Wiater, Ewa Lech‐Marańda, Joanna Mańko et al. · 2013 · Acta Haematologica Polonica
23. Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study
    Damian Mikulski, Pawel J. Robak, Wiktoria Ryżewska, Kamila Stańczak, Kacper Kościelny, Joanna Góra‐Tybor, Tadeusz Robak · 2022 · Journal of Clinical Medicine
24. Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego na rok 2012
    Anna Dmoszyńska, Adam Walter‐Croneck, Joanna Mańko, Lidia Usnarska‐Zubkiewicz, Beata M. Stella-Holowiecka, Jan Andrzej Walewski, Grzegorz Charliński, W Wiktor-Jędrzejczak, Elżbieta Wiater, Ewa Lech‐Marańda et al. · 2012 · Acta Haematologica Polonica
25. Novel agents in myeloma: An exciting saga
    Tomer Martin Mark, Rubén Niesvizky, Morton Coleman · 2008 · Cancer
26. Allogeneic Stem Cell Transplantation and Targeted Immunotherapy for Multiple Myeloma
    Ivetta Danylesko, Avichai Shimoni, Arnon Nagler · 2013 · Clinical Lymphoma Myeloma & Leukemia
27. Optimal management of elderly patients with myeloma
    C. Cerrato, Roberto Mina, A. Palumbo · 2014 · Expert Review of Anticancer Therapy
28. Prognostic factors and outcome in relapsed multiple myeloma after nonmyeloablative allo-SCT: a single center experience
    Monique C. Minnema, Suzanne van Dorp, Niels W.C.J. van de Donk, F Schouten, Marie José Kersten, J.L. Coenen, Harry C. Schouten, Sonja Zweegman, Ron Schaafsma, Henk M. Lokhorst · 2010 · Bone Marrow Transplantation
29. Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications–2
    Rafael Fonseca, Paul Gerard Guy Richardson, Sergio Giralt, Sagar Lonial, S Vincent Rajkumar, A Keith Stewart, William Bensinger, George Somlo, Robert Vescio, Joseph Mikhael et al. · 2010 · Mayo Clinic Proceedings
30. Choosing treatment options for patients with relapsed/refractory multiple myeloma
    Roberto Castelli, Nicola Orofino, Agnese Losurdo, Roberta Gualtierotti, Massimo Cugno · 2013 · Expert Review of Anticancer Therapy
31. Personalizing Lung Cancer Prevention Through a Reverse Migration Strategy
    Kathryn Ann Gold, Edward S. Kim, Ignacio Ivan Wistuba, Waun Ki Hong · 2012 · Topics in current chemistry
32. Maintenance therapy in newly diagnosed multiple myeloma: current recommendations
    Annamaria Brioli, Paola Tacchetti, Elena Zamagni, Michèle Cavo · 2014 · Expert Review of Anticancer Therapy
33. Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults
    Emily Jean Guerard, Sascha Alexander Tuchman · 2015 · Clinics in Geriatric Medicine
34. Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma
    Haruhito Totani, Masaki Ri, Chie Kato, Takahiro Nakashima, Nana Suzuki, Shinya Hagiwara, Takashi Kanamori, Satsuki Murakami, Arisa Masuda, Shiori Kinoshita et al. · 2015 · International Journal of Hematology
35. Supportive Therapies in Multiple Myeloma
    Charise L. Gleason, Ajay K. Nooka, Sagar Lonial · 2009 · Journal of the National Comprehensive Cancer Network
36. Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials
    Wolfgang Ulrich Knauf, Ali Aldaoud, Christoph J. Losem, Johann Mittermueller, Michael Neise, Beate Niemeier, Johanna Harde, Tanja Trarbach, Karin Potthoff · 2018 · Leukemia Research
37. Impact of chromosomal abnormalities on the efficacy of lenalidomide plus dexamethasone treatment in patients with relapsed/refractory multiple myeloma
    Takashi Yoshida, Masaki Ri, Haruna Fujinami, Yoshiko Oshima, Takuto Tachita, Yoshiaki Marumo, Hirokazu Sasaki, Shiori Kinoshita, Haruhito Totani, Tomoko Narita et al. · 2019 · International Journal of Hematology
38. AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma
    Sikander Ailawadhi, Ricardo Daniel Parrondo, Navnita Dutta, Bing Han, Gina Ciccio, Yesesri Cherukuri, Victoria R. Alegria, Betsy R LaPlant, Vivek Roy, Taimur Sher et al. · 2023 · Cancers
39. Multiple myeloma with extramedullary plasmacytoma invading the skin and eyeballs following autologous stem cell transplantation: A case report
    Guangzhong Yang, Chuanying Geng, Yanchen Li, Aijun Liu, Wen-Ming Chen · 2013 · Experimental and Therapeutic Medicine
40. KRN5500, a spicamycin derivative, exerts anti‐myeloma effects through impairing both myeloma cells and osteoclasts
    Hirokazu Miki, Shuji Ozaki, Shingen Nakamura, Asuka Oda, Hiroe Amou, Akishige Ikegame, Keiichiro Watanabe, Masahiro Hiasa, Qu Cui, Takeshi Harada et al. · 2011 · British Journal of Haematology
41. Treatment of relapsed and refractory myeloma
    Jonathan L. Kaufman, Charise L. Gleason, Sagar Lonial · 2009 · Current Hematologic Malignancy Reports
42. Therapeutic options for HIV-associated lymphomas
    Michele Spina, Annunziata Gloghini, Umberto Tirelli, Antonino Carbone · 2010 · Expert Opinion on Pharmacotherapy
43. Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data
    Istvan Matyas Majer, Gijs van de Wetering, Zoltán Polányi, Arun Krishna, Elisabeth Gray, Anuja Nidumolu Roy · 2016 · Applied Health Economics and Health Policy
44. Novel Therapies for Relapsed/Refractory Multiple Myeloma: How Can We Improve on “Salvage” Therapy?—Introduction
    Andrzej J. Jakubowiak · 2012 · Seminars in Hematology
45. Lenalidomide in combination with dexamethasone induced rhabdomyolysis in a multiple myeloma patient treated with pravastatin
    Chisako Urata, Mariko Yoshimura, Hidekazu Itamura, Takashi Hisatomi, Yasushi Kubota, Noriyasu Fukushima, Eisaburo Sueoka, Shinya H Kimura · 2011 · International Journal of Hematology
46. New treatments in multiple myeloma: beyond optimal treatment
    Jean‐Luc Harousseau · 2008 · Annals of Oncology
47. First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Recommendations From a Canadian Consensus Guideline Consortium
    Sahar Khan, Debra J. Bergstrom, Julie Anne Côté, Rami R. Kotb, Richard LeBlanc, Martha Louzada, Hira S. Mian, Ibraheem Othman, Gabriele Colasurdo, Alissa Visram · 2024 · Clinical Lymphoma Myeloma & Leukemia
48. Incorporating Novel Agents in the Management of Elderly Myeloma Patients
    Tommasina Guglielmelli, Antonio Pierangelo Palumbo · 2013 · Current Hematologic Malignancy Reports
49. Evolving Strategies in the Initial Treatment of Multiple Myeloma
    Cara Ann Rosenbaum, Jagoda K. Jasielec, Jacob P. Laubach, Claudia Paba Prada, Paul Gerard Guy Richardson, Andrzej J. Jakubowiak · 2013 · Seminars in Oncology
50. Addition of Cyclophosphamide “On Demand” to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma—A Retrospective Review of a Single-center Experience
    Majed D. Alahmadi, Esther Masih‐Khan, Eshetu G. Atenafu, Christine I. Chen, Vishal Kukreti, Rodger Edwin Tiedemann, Suzanne Trudel, Donna Ellen Reece · 2018 · Clinical Lymphoma Myeloma & Leukemia
51. The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study)
    the Korean Multiple Myeloma Working Party (KMMWP), Jae‐Cheol Jo, Ho Sup Lee, Kihyun Kım, Je‐Jung Lee, Sung‐Soo Yoon, Soo‐Mee Bang, Jin Seok Kim, Hyeon‐Seok Eom, Dok Hyun Yoon et al. · 2019 · Annals of Hematology
52. Multiple myeloma etiology and treatment
    Humaira Sadaf, Hanna Hong, Mohsin Maqbool, Kylin A. Emhoff, Jianhong Lin, Shan Yan, Faiz Anwer, Jianjun Zhao · 2022 · Journal of Translational Genetics and Genomics
53. Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy
    Junya Kuroda, Tsutomu Kobayashi, Masafumi Taniwaki · 2015 · Expert Review of Anticancer Therapy
54. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Michel Delforge, A Michiels, Chantal Doyen, Alain Kentos, Jan Van Droogenbroeck, Fritz C. Offner, Greet Bries, H Demuynck, Marie Christiane Vekemans, Nathalie Meuleman et al. · 2011 · PubMed
55. Initial testing of lenalidomide by the pediatric preclinical testing program
    C. Patrick Reynolds, Min H. Kang, Stephen Thomas Keir, Richard Greg Gorlick, Edward Anders Kolb, Richard B. Lock, John M. Maris, Hernán Carol, Christopher L. Morton, Catherine A. Billups et al. · 2011 · Pediatric Blood & Cancer
56. Alemtuzumab-Based Reduced-Intensity Conditioning Allogeneic Transplantation for Myeloma and Plasma Cell Leukemia – A Single-Institution Experience
    Karthik Ramasamy, Shameem Mahmood, ZiYi Lim, Sophie Corderoy, Stephen Devereux, Ghulam Jeelani Mufti, Antonio Pagliuca, Stephen Schey · 2011 · Clinical Lymphoma Myeloma & Leukemia
57. Achieving an Early Myeloma Response in Patients With Kidney Impairment
    Stephanie J. Stringer, Mark A. Cook, Paul Cockwell · 2012 · Advances in Chronic Kidney Disease
58. Immunomodulatory agents in oncology
    Todd M. Zimmerman · 2009 · Update on Cancer Therapeutics
59. Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma
    Rabindra Kumar Jena, Trupti Rekha Swain, Sandeep Sadashivrao Kansurkar, Manorama Swain · 2011 · European Journal of Clinical Pharmacology
60. Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma
    Sara Bringhen, Francesca Gay, Francesca Donato, Rossella Troia, Roberto Mina, Antonio Pierangelo Palumbo · 2014 · Expert Opinion on Investigational Drugs
61. Sequential or combination therapy for multiple myeloma
    Ajay K. Nooka, Sagar Lonial · 2012 · Expert Review of Hematology
62. Evidence-based case report: multiple thrombotic episodes associated with lenalidomide and dexamethasone therapy for multiple myeloma
    Gordon F. Rushworth, Stephen James Leslie, Peter D. Forsyth, Claire Vincent · 2012 · Therapeutic Advances in Drug Safety
63. Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent
    Patrizia Mondello, Vincenzo V. Pitini, Valeria Barresi, Elliott Joseph Brea, Cristian Di Mirto, Carmela Arrigo, Salvatore Cuzzocrea, Michael Mian · 2015 · Experimental Hematology and Oncology
64. Novel combination approaches for myeloma
    Sagar Lonial, Ajay K. Nooka · 2015 · Hematology
65. Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
    Nishitha Thumallapally, Hana Yu, Divya Asti, Adarsh Vennepureddy, Tering Terjanian · 2016 · OncoTargets and Therapy
66. Pathophysiology and Clinical Aspects of Venous Thromboembolism in Neonates, Renal Disease and Cancer Patients
    Mohamed Abdelaal · 2012 · InTech eBooks
67. Targeting the Bone Marrow Niche in Hematological Malignancies
    Divij Verma, Daniela S. Krause · 2017 · Advances in stem cells and their niches
68. Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide
    Atsushi Isoda, Naru Sato, Yuri Miyazawa, Yoshinobu Matsumoto, Mina Koumoto, Masahito Ookawa, Morio Sawamura, Morio Matsumoto · 2015 · International Journal of Hematology
69. Short-courses of dexamethasone abolish bisphosphonate-induced reductions in bone toughness
    Tianyi David Luo, Matthew R. Allen · 2013 · Bone
70. Néphrotoxicité du lénalidomide
    Rania El Fekih, Hassan Izzedine · 2016 · Bulletin du Cancer
71. Renal, GI, and Peripheral Nerves: Evidence-Based Recommendations for the Management of Symptoms and Care for Patients With Multiple Myeloma
    Beth M Faiman, Deborah Doss, Kathleen Colson, Patricia Mangan, Tracy King, Joseph D Tariman, and Board · 2017 · Clinical journal of oncology nursing
72. Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
    Fukuoka Blood and Marrow Transplantation Group, Yasuo Mori, Ilseung Choi, Goichi Yoshimoto, Tsuyoshi Muta, Satoshi Yamasaki, Kazuki Tanimoto, Tomohiko Kamimura, Hiromi Iwasaki, Ryosuke Ogawa et al. · 2020 · International Journal of Hematology
73. Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone
    Ho Sup Lee, Kihyun Kım, Je‐Jung Lee, Sung‐Soo Yoon, Soo‐Mee Bang, Jin Seok Kim, Hyeon‐Seok Eom, Dok Hyun Yoon, Yoojin Lee, Ho‐Jin Shin et al. · 2020 · International Journal of Hematology
74. Nouvelles thérapies du myélome
    I Azaïs, Rachel Brault, Françoise Debiais · 2010 · Revue du Rhumatisme
75. Evolving Role of Novel Agents for Maintenance Therapy in Myeloma
    Valeria Magarotto, Antonio Pierangelo Palumbo · 2009 · The Cancer Journal
76. Carfilzomib in multiple myeloma: gold, silver, or bronze?
    Donna Ellen Reece · 2012 · Blood
77. Lenalidomide in multiple myeloma
    Bhawna Sirohi, R Powles · 2009 · Expert Review of Anticancer Therapy
78. Long-Term Disease Stabilization in a Patient with Castration-Resistant Metastatic Prostate Cancer by the Addition of Lenalidomide to Low-Dose Dexamethasone and Celecoxib
    Norbert Walter Marschner, Matthias R. Zaiss · 2012 · Onkologie
79. Multiple myeloma: the quality of care is linked to geographical and organisational determinants. A study in a French registry
    Mathieu Puyade, Gautier Défossez, François Guilhot, Pierre Ingrand · 2015 · European Journal of Cancer Care
80. The evolving role of lenalidomide in non-Hodgkin lymphoma
    Natalie Galanina, Adam Matthew Petrich, Chadi Nabhan · 2016 · Leukemia & lymphoma/Leukemia and lymphoma
81. Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide
    Kazuhito Suzuki, Kaichi Nishiwaki, Tadahiro Gunji, Mitsuji Katori, Hidekazu Masuoka, Shingo Yano · 2020 · Cancer Medicine
82. Low cerebrospinal fluid-to-plasma ratios of orally administered lenalidomide mediated by its low cell membrane permeability in patients with hematologic malignancies
    Daisuke Ogiya, Norie Murayama, Yusuke Kamiya, Rie Saito, Sawako Shiraiwa, Rikio Suzuki, Shinichiro Machida, Kei Tazume, Kiyoshi Ando, Hiroshi Yamazaki · 2022 · Annals of Hematology
83. Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic Review
    Tung-Lung Yang, Chin S. Lin, Ching‐Liang Ho, Tzu‐Chuan Huang, Yi‐Ying Wu, Hong‐Jie Jhou, Po‐Huang Chen, Cho‐Hao Lee · 2023 · Life
84. Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide
    Ayşe Salihoğlu, Muhlis Cem Ar, Teoman Soysal · 2015 · Expert Review of Hematology
85. Novel agents and the paradigm of continuous treatment in multiple myeloma
    Antonio Pierangelo Palumbo · 2012 · Leukemia Research
86. Lenalidomide plus dexamethasone is effective in multiple myeloma
    Ellen Meijer, Pieter Sonneveld · 2009 · Nature Reviews Clinical Oncology
87. Novel Treatments for T-Cell Lymphoma
    Chan Yoon Cheah, Yasuhiro Oki, Michelle A. Fanale · 2015 · American Society of Clinical Oncology Educational Book
88. Genetic and Molecular Epidemiology of Multiple Myeloma
    Lentzsch, Suzanne · 2013 · Springer eBooks
89. Lenalidomide with Dexamethasone to Multiple Myeloma Patients Relapsing from Bortezomib-Based Induction Therapies: a Prospective, Observational Study
    Tran‐Der Tan, Ying‐Chung Hong, Sin‐Syue Li, Jui‐Ting Yu, Yung-Chuan Sung, Po-Nan Wang, Chieh‐Lin Jerry Teng · 2020 · The Chinese Journal of Physiology
90. Practical guidance for new multiple myeloma treatment regimens: A nursing perspective
    Monica Epstein, Candis Morrison · 2022 · Seminars in Oncology
91. Multinomial network meta-analysis using response rates: relapsed/refractory multiple myeloma treatment rankings differ depending on the choice of outcome
    Chrissy H.Y. van Beurden-Tan, Pieter Sonneveld, Carin A. Uyl‐de Groot · 2022 · BMC Cancer
92. Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft‐versus‐host disease by inhibiting T‐cell migration to the gastrointestinal tract
    Yukie� Tsubokura, Hideaki� Yoshimura, Atsushi� Satake, Yutaro Nasa, Ryohei Tsuji, Tomoki� Ito, Shosaku� Nomura · 2022 · Immunity Inflammation and Disease
93. Current application of dexamethasone-incorporated drug delivery systems for enhancing bone formation
    Thi Phuong Mai, Jun‐Beom Park, Huu Duc Nguyen, Kyoung Ah Min, Cheol Moon · 2023 · Journal of Pharmaceutical Investigation
94. Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide
    Shigeki Ito, Tatsuo Oyake, Kazunori Murai, Yoji Ishida · 2013 · Case Reports in Hematology
95. Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting
    Megan M. Sharkey, Daniel McKavanagh, Euan Thomas Walpole, Peter N. Mollee, Samantha Hollingworth · 2017 · International Journal of Clinical Pharmacy
96. Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma
    Tadao Ishida, Hideo Kimura, Shuji Ozaki, Koumei Kubo, Kazutaka Sunami, Naoki Takezako, Hiroyuki Fujita, Toshiaki Hayashi, Toru Kiguchi, Kazuteru Ohashi et al. · 2020 · Annals of Hematology
97. Withdrawal of hospital outpatient treatments in severe diseases due to unacceptable toxicity: A retrospective study from the register of patients and treatments
    Antònia Agustí, Cristina Aguilera, Montserrat Bosch, Imma Danés, E. Pérez, Lourdes Vendrell, Marta-Beatriz Aller, Núria Boixareu, Núria García‐Doladé, Eduard Diogène · 2020 · British Journal of Clinical Pharmacology
98. Newly diagnosed multiple myeloma in Taiwan
    Chung‐King Lin, Yung‐Chuan Sung · 2009 · Hematology/Oncology and Stem Cell Therapy
99. Novel Therapies in Multiple Myeloma for Newly Diagnosed Nontransplant Candidates
    Sigurdur Yngvi Kristinsson, Ola Landgren, S. Vincent Rajkumar · 2009 · The Cancer Journal
100. Pomalidomide (CC4047) plus Low-Dose Dexamethasone (Pom/Dex) as Therapy for Relapsed Multiple Myeloma
     Martha Q. Lacy, Suzanne R. Hayman, Morie Abraham Gertz, Angela A. Dispenzieri, Stephen R. Zeldenrust, Shaji Kunnathu Kumar, Philip R. Greipp, John Anthony Lust, Stephen J. Russell, Francis K. Buadi et al. · 2009 · Clinical Lymphoma & Myeloma